Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
“2023 was a year of significant accomplishment and foundational progress for Nautilus; progress that will continue to build our momentum as we move through 2024 and into the planned launch of our proteome analysis platform”, said Sujal Patel, CEO of Nautilus. “We are building a groundbreaking, ‘first-in-the-world’ platform designed to unlock significant breakthroughs in biological research. Doing so requires that a number of meaningful innovations across each element of our platform - consumables, instrument, and software - weave together seamlessly. We continue to refine each of these platform elements and look forward to getting the collective work of our team into the hands of researchers where it can do so much good. I’m particularly pleased that we’ve been able to drive such meaningful scientific progress while maintaining exceptional fiscal discipline and preserving our balance sheet.”
Fiscal Year 2023 Financial Results
Operating expenses were $76.2 million for the year ended December 31, 2023, a $12.5 million or 20% increase from $63.6 million for the year ended December 31, 2022. The increase in operating expenses was driven primarily by an increase in headcount to support ongoing development of our products.
Net loss was $63.7 million for the year ended December 31, 2023, as compared to a net loss of $57.9 million for the corresponding prior year period.
Cash, cash equivalents, and investments were $264.1 million as of December 31, 2023.
Fiscal Year 2024 Outlook
- We expect full year operating expense to grow by approximately 25% relative to 2023
- We expect that cash and cash equivalents and investments of $264.1 million as of December 31, 2023 to provide a runway into the second half of 2026
- We expect to launch our platform, instruments, consumables, and software in 2025.
Webcast and Conference Call Information
Nautilus will host a conference call to discuss the fourth quarter and fiscal year 2023 financial results, business developments and outlook before market open on Wednesday, February 28, 2024 at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, financial performance and results of operations; expectations with respect to any revenue timing or projections, expectations with respect to the timing of the launch of Nautilus’ product platform and full commercial availability, the functionality and performance of Nautilus’ product platform, its potential impact on providing proteome access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery, and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K to be filed for the year ended December 31, 2023 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Disclosure Information
Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
| Nautilus Biotechnology, Inc. Consolidated Balance Sheets As of December 31, 2023 and 2022 (Unaudited) |
| (in thousands, except share and per share amounts) | December 31, 2023 | December 31, 2022 | |||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 19,397 | $ | 114,523 | |||
| Short-term investments | 154,021 | 69,948 | |||||
| Prepaid expenses and other current assets | 3,419 | 2,738 | |||||
| Total current assets | 176,837 | 187,209 | |||||
| Property and equipment, net | 4,267 | 3,700 | |||||
| Operating lease right-of-use assets | 32,634 | 28,866 | |||||
| Long-term investments | 90,647 | 129,169 | |||||
| Other long-term assets | 1,180 | 1,108 | |||||
| Total assets | $ | 305,565 | $ | 350,052 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,639 | $ | 1,272 | |||
| Accrued expenses and other liabilities | 3,945 | 3,528 | |||||
| Current portion of operating lease liability | 3,538 | 1,991 | |||||
| Total current liabilities | 9,122 | 6,791 | |||||
| Operating lease liability, net of current portion | 31,090 | 28,337 | |||||
| Total liabilities | 40,212 | 35,128 | |||||
| Stockholders’ equity: | |||||||
| Preferred stock | — | — | |||||
| Common stock | 13 | 12 | |||||
| Additional paid-in capital | 467,834 | 455,330 | |||||
| Accumulated other comprehensive loss | (255 | ) | (1,854 | ) | |||
| Accumulated deficit | (202,239 | ) | (138,564 | ) | |||
| Total stockholders’ equity | 265,353 | 314,924 | |||||
| Total liabilities and stockholders’ equity | $ | 305,565 | $ | 350,052 | |||
| Nautilus Biotechnology, Inc. Consolidated Statements of Operations Three Months and Year Ended December 31, 2023 and 2022 (Unaudited) |
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| (in thousands, except share and per share amounts) | 2023 | 2022 | 2023 | 2022 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 12,466 | $ | 9,587 | $ | 47,251 | $ | 37,672 | |||||||
| General and administrative | 7,535 | 6,717 | 28,901 | 25,946 | |||||||||||
| Total operating expenses | 20,001 | 16,304 | 76,152 | 63,618 | |||||||||||
| Other income (expense): | |||||||||||||||
| Interest income | 3,033 | 2,887 | 12,550 | 5,816 | |||||||||||
| Other expense | (56 | ) | 8 | (73 | ) | (122 | ) | ||||||||
| Total other income | $ | 2,977 | $ | 2,895 | $ | 12,477 | $ | 5,694 | |||||||
| Net loss | $ | (17,024 | ) | $ | (13,409 | ) | $ | (63,675 | ) | $ | (57,924 | ) | |||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.14 | ) | $ | (0.11 | ) | $ | (0.51 | ) | $ | (0.46 | ) | |||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 124,984,918 | 124,789,542 | 124,919,144 | 124,589,555 | |||||||||||
| Nautilus Biotechnology, Inc. Consolidated Statements of Cash Flows Year Ended December 31, 2023 and 2022 (Unaudited) |
| Year Ended December 31, | |||||||
| (in thousands) | 2023 | 2022 | |||||
| Cash flows from operating activities | |||||||
| Net loss | $ | (63,675 | ) | $ | (57,924 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities | |||||||
| Stock-based compensation | 12,137 | 10,380 | |||||
| Amortization of operating lease right-of-use assets | 3,856 | 2,199 | |||||
| Depreciation | 1,849 | 1,217 | |||||
| Amortization (accretion) of premiums (discount) on securities, net | (2,659 | ) | (890 | ) | |||
| Changes in operating assets and liabilities: | |||||||
| Prepaid expenses and other assets | (821 | ) | 756 | ||||
| Accounts payable | 393 | (561 | ) | ||||
| Accrued expenses and other liabilities | 417 | 409 | |||||
| Operating lease liabilities | (3,208 | ) | (1,392 | ) | |||
| Net cash used in operating activities | (51,711 | ) | (45,806 | ) | |||
| Cash flows from investing activities | |||||||
| Purchases of securities | (112,892 | ) | (186,591 | ) | |||
| Purchases of property and equipment | (2,442 | ) | (2,324 | ) | |||
| Proceeds from maturities of securities | 71,599 | 163,175 | |||||
| Net cash used in investing activities | (43,735 | ) | (25,740 | ) | |||
| Cash flows from financing activities | |||||||
| Proceeds from exercise of stock options | 104 | 330 | |||||
| Proceeds from issuance of common stock under employee stock purchase plan | 264 | 232 | |||||
| Net cash provided by financing activities | 368 | 562 | |||||
| Net decrease in cash, cash equivalents and restricted cash | (95,078 | ) | (70,984 | ) | |||
| Cash, cash equivalents and restricted cash at beginning of period | 115,477 | 186,461 | |||||
| Cash, cash equivalents and restricted cash at end of period | $ | 20,399 | $ | 115,477 | |||
